Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Seed Healthcare Invests in Diadem for US Alzheimer's Diagnostic Launch

25 August 2026 · By · Wire by Fusion42

Published

25 August 2026

Topic

opportunities

◆ Sectors

Healthtech Infrastructure

◆ Geography

United States

◆ Source

Read at clpmag.com →

◆ Verified

Fusion42 · 26 August 2026 · Fusion42 review

Seed Healthcare has led an investment in Diadem to support US commercialization of a blood-based Alzheimer’s diagnostic technology that enables early detection and prognostic testing, aiming to integrate it into routine clinical care.

This Wire brief sits within Fusion42's coverage of Healthtech Infrastructure.

◆ ◆ The Wire takeaway

You can now pitch early Alzheimer’s detection as a practical clinical tool supported by a US-ready blood test. Building partnerships with diagnostic innovators like Diadem is your quickest route into neurological care workflows.

◆ Coverage

1 source · 25 Aug 2026

◆ Related on Wire

◆ Topics

Healthtech Infrastructurealzheimersdiagnosticsearly-detectionhealthtechblood-based-testing